専　門

• 消化器病学
• 肝臓病学
• 肝臓がんの診断と治療

所属学会

• 日本内科学会認定医、総合内科専門医・指導医
• 日本消化器病学会専門医・指導医
• 日本肝臓学会専門医・指導医
• 日本IVR学会専門医
• がん薬物療法専門医
• 日本がん治療認定機構がん治療認定医、日本がん治療認定医機構教育委員
• 日本医師会認定産業医
• 日本消化器病学会学会評議員、近畿支部評議員
• 日本肝臓学会評議員、西部会評議員
• 日本肝癌研究会社員
• リザーバー研究会世話人

主な研究業績

1. Sato R, Moriguchi M, et al. Real-world outcomes of molecular targeted agents for patients with hepatocellular carcinoma over 80 years old. Hepatol Res. 2022 Oct;52(10):859-871.
2. Ueshima K, Komemushi A, Aramaki T, Iwamoto H, Obi S, Sato Y, Tanaka T, Matsueda K, Moriguchi M, et al. Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment. Liver Cancer. 2022 May 5;11(5):407-425.
3. Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Moriguchi M, et al. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer. 2022 Feb 10;11(4):354-367.
4. Seko Y, Moriguchi M, et al. Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. J Gastroenterol. 2022 Feb;57(2):90-98.
5. Kobayashi K, Ogasawara S, Takahashi A, Seko Y, Unozawa H, Sato R, Watanabe S, Moriguchi M, et al. Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer. 2021 Dec 6;11(1):48-60.
6. Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, et al. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer. 2021 Jun;10(3):181-223.
7. Kudo M, Morimoto M, Moriguchi M, et al. A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. Cancer Sci. 2020 Oct;111(10):3759-3769.
8. Aramaki T, Arai Y, Takeuchi Y, Sone M, Sato R, Bekku E, Moriguchi M. A randomized, controlled trial of the efficacy of percutaneous transesophageal gastro-tubing (PTEG) as palliative care for patients with malignant bowel obstruction: the JIVROSG0805 trial. Support Care Cancer. 2020 Jun;28(6):2563-2569.
9. Moriguchi M, et al. Intrahepatic Tumor Burden as a Novel Factor Influencing the Introduction of Second-line Chemotherapy for Hepatocellular Carcinoma. Anticancer Res. 2020 in press
10. Takahashi A, Moriguchi M, et al. Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis. Cancers (Basel). 2020;12(3):754.
11. Moriguchi M, et al. Epidemiology of hepatocellular carcinoma in nonalcoholic fatty liver disease. Hepatoma Res 2019;5:43
12. Takahashi A, Moriguchi M, et al. Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. Anticancer Res. 2019;39(9):5149-5156.
13. Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, et al. Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis. J Hepatol. 2019;71(3):543-552.
14. Furuta M, Moriguchi M, et al. Impact of insufficient response with an increase in tumor number in predicting transcatheter arterial chemoembolization refractoriness for hepatocellular carcinoma. Dig Dis. 2018;36(5):385-394.
15. Kudo M, Moriguchi M, et al. S1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomized, double-blind, multicentre, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(6):407-417.
16. Moriguchi M, et al. Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular carcinoma with Advanced Portal Vein Tumor Thrombosis. Liver Cancer. 2017;6(4):275-286.
17. Moriguchi M, et al. A Review of Non-Operative Treatments for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombus. Journal of Clinical and Translational Hepatology. J Clin Transl Hepatol. 2017;5(2):177-183.
18. Moriguchi M, et al. Hepatic arterial infusion chemotherapy with cisplatin for TACE-refractory or –ineligible hepatocellular carcinoma with a Child-Pugh score of 8 or above. Hepat Mon 2017; 17(2):e43627.
19. Moriguchi M, et al. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma. Clin J Gastroenterol. 2016;9(4):184-90.
20. Okusaka T, Aramaki T, Inaba Y, Nakamura S, Morimoto M, Moriguchi M, et al. Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors. Cancer Sci. 2015;106(5):611-7.
21. Yamakawa Y, Moriguchi M, et al. Brain metastasis from hepatocellular carcinoma: The impact of radiotherapy on control of intracranial hemorrhage. Hepatol Res. 2015;45(11):1071-5.
22. Aramaki T, Moriguchi M, et al. Comparison of epirubicin hydrochloride and miriplatin hydrate as anticancer agents for transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatol Res. 2013;43(5):475-80.
23. Moriguchi M, et al. The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. Int J Cancer. 2002;102(5):445-52.